IL145634A0 - Methods of treating leukemia - Google Patents

Methods of treating leukemia

Info

Publication number
IL145634A0
IL145634A0 IL14563400A IL14563400A IL145634A0 IL 145634 A0 IL145634 A0 IL 145634A0 IL 14563400 A IL14563400 A IL 14563400A IL 14563400 A IL14563400 A IL 14563400A IL 145634 A0 IL145634 A0 IL 145634A0
Authority
IL
Israel
Prior art keywords
group
treating leukemia
methods
alkynyl
alkenyl
Prior art date
Application number
IL14563400A
Other languages
English (en)
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of IL145634A0 publication Critical patent/IL145634A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/03—Compounds acting on the NO pathway, e.g. nitrososarginine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14563400A 1999-03-29 2000-03-28 Methods of treating leukemia IL145634A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12673499P 1999-03-29 1999-03-29
US12681399P 1999-03-30 1999-03-30
PCT/CA2000/000334 WO2000057861A2 (en) 1999-03-29 2000-03-28 Use of cytidine derivatives for the treatment of leukaemia

Publications (1)

Publication Number Publication Date
IL145634A0 true IL145634A0 (en) 2002-06-30

Family

ID=26824972

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14563400A IL145634A0 (en) 1999-03-29 2000-03-28 Methods of treating leukemia
IL145634A IL145634A (en) 1999-03-29 2001-09-25 Use of nucleoside analogues in drugs to treat leukemia
IL173586A IL173586A0 (en) 1999-03-29 2006-02-07 Use of nucleoside analogues and doxorubicin in medicaments for treating leukemia

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL145634A IL145634A (en) 1999-03-29 2001-09-25 Use of nucleoside analogues in drugs to treat leukemia
IL173586A IL173586A0 (en) 1999-03-29 2006-02-07 Use of nucleoside analogues and doxorubicin in medicaments for treating leukemia

Country Status (24)

Country Link
US (3) US6630480B1 (enExample)
EP (2) EP2138179A1 (enExample)
JP (1) JP2002540142A (enExample)
KR (2) KR20020000554A (enExample)
CN (1) CN1297281C (enExample)
AT (1) ATE442151T1 (enExample)
AU (1) AU773437C (enExample)
BR (1) BR0009378A (enExample)
CA (1) CA2366012A1 (enExample)
CZ (1) CZ20013483A3 (enExample)
DE (1) DE60042921D1 (enExample)
DK (1) DK1165096T3 (enExample)
ES (1) ES2333399T3 (enExample)
HK (1) HK1041828B (enExample)
HU (1) HUP0201708A3 (enExample)
IL (3) IL145634A0 (enExample)
IS (1) IS6086A (enExample)
MX (1) MXPA01009888A (enExample)
NO (1) NO323840B1 (enExample)
NZ (1) NZ529882A (enExample)
PL (1) PL351500A1 (enExample)
SK (1) SK13822001A3 (enExample)
WO (1) WO2000057861A2 (enExample)
ZA (1) ZA200107963B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
ATE269081T1 (de) 1999-09-24 2004-07-15 Shire Biochem Inc Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
CA2425359A1 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
WO2002076472A2 (en) * 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
US7158517B2 (en) 2001-05-21 2007-01-02 Intel Corporation Method and apparatus for frame-based protocol processing
CA2465682A1 (en) 2001-11-02 2003-05-08 Shire Biochem Inc. Methods of treating leukemia
AU2003291882A1 (en) * 2002-12-06 2004-06-30 Shire Biochem Inc. Pharmaceutical combinations and methods for the treatment of leukemia
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20040248915A1 (en) * 2003-04-25 2004-12-09 Jacques Jolivet Method for administration of troxacitabine
US8932649B2 (en) * 2003-11-14 2015-01-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds
KR100708016B1 (ko) * 2004-01-20 2007-04-16 한국쓰리엠 주식회사 스탠드의 전후좌우 회전장치
US7605137B2 (en) * 2004-03-26 2009-10-20 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine
SG175599A1 (en) * 2006-01-31 2011-11-28 Array Biopharma Inc Kinase inhibitors and methods of use thereof
US8026233B2 (en) 2006-03-29 2011-09-27 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US9262697B2 (en) * 2006-09-25 2016-02-16 Cambridge Research & Instrumentation, Inc. Sample imaging and classification
WO2008075370A2 (en) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
KR101573026B1 (ko) * 2007-07-25 2015-11-30 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
EA022915B1 (ru) * 2007-10-09 2016-03-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы лечения острого миелоидного лейкоза и миелодиспластического синдрома
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270315A (en) 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
KR920701355A (ko) 1989-06-05 1992-08-11 존 디. 후써 내충격성 중합체 혼합물
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
KR102127978B1 (ko) * 2014-01-10 2020-06-29 삼성전자주식회사 구조도 생성 방법 및 장치

Also Published As

Publication number Publication date
ZA200107963B (en) 2003-01-02
DK1165096T3 (da) 2010-01-25
IL145634A (en) 2006-06-11
DE60042921D1 (de) 2009-10-22
AU3546600A (en) 2000-10-16
ES2333399T3 (es) 2010-02-22
AU773437B2 (en) 2004-05-27
CZ20013483A3 (cs) 2002-04-17
PL351500A1 (en) 2003-04-22
HUP0201708A3 (en) 2005-02-28
IS6086A (is) 2001-09-26
US6747036B2 (en) 2004-06-08
KR20020000554A (ko) 2002-01-05
WO2000057861A2 (en) 2000-10-05
EP2138179A1 (en) 2009-12-30
CN1345242A (zh) 2002-04-17
HUP0201708A1 (en) 2002-10-28
EP1165096B1 (en) 2009-09-09
WO2000057861A3 (en) 2001-03-08
AU773437C (en) 2005-02-17
MXPA01009888A (es) 2003-07-21
IL173586A0 (en) 2006-07-05
NZ529882A (en) 2005-05-27
US20020107225A1 (en) 2002-08-08
JP2002540142A (ja) 2002-11-26
NO20014727D0 (no) 2001-09-28
HK1041828A1 (en) 2002-07-26
US20040192654A1 (en) 2004-09-30
CN1297281C (zh) 2007-01-31
ATE442151T1 (de) 2009-09-15
SK13822001A3 (sk) 2002-02-05
EP1165096A2 (en) 2002-01-02
US6630480B1 (en) 2003-10-07
HK1041828B (en) 2010-04-30
BR0009378A (pt) 2002-01-08
NO323840B1 (no) 2007-07-09
NO20014727L (no) 2001-11-08
CA2366012A1 (en) 2000-10-05
KR20050005569A (ko) 2005-01-13

Similar Documents

Publication Publication Date Title
IL145634A0 (en) Methods of treating leukemia
IL148903A0 (en) Certain alkylene diamine-substituted heterocycles
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
EP1617840A4 (en) PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ZA977698B (en) Substituted cyclic amine metalloprotease inhibitors.
EP1622616A4 (en) HEMMER OF ACT ACTIVITY
ATE167679T1 (de) Wirkstoffvorläufer von phosphonaten
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
EP0826688A4 (en) PENTACYCLIC COMPOUNDS
AU674639B2 (en) 3'-substituted nucleoside derivatives
WO2000026225A3 (en) Nucleosides with anti-hepatitis b virus activity
WO2002078678A3 (en) Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
EP1101767A3 (en) Oligosiloxane and method of preparing same
EP0799040A4 (en) TRISUBSTITUTED THIOXANTHINES
WO2001012642A3 (de) Nucleosidderivate und verfahren zu deren herstellung
EP0372409A3 (en) Acylaminoalkylpyridineamides as inhibitors of tumor metastasis
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed